In addition to the aforementioned imaging biomarker, cerebrospinal fluid (CSF) Aβ (Aβ42/Aβ40 ratio, Aβ42) and phosphorylated tau (P-tau) biomarkers have been established in the routine clinical practice for assisting the diagnosis of AD (Hansson et al., 2019, 2021). This evidence concerns the gene MAPT and Alzheimer disease.